Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP

Nucl Med Biol. 1997 Jan;24(1):27-33. doi: 10.1016/s0969-8051(96)00151-5.


Technetium-99m-labeled alendronate is a new radiopharmaceutical for bone scanning developed under strict quality control at the INNSZ. The purpose of this work was to compare the radiopharmacokinetic data and the dosimetry of 99mTc-ABP and 99mTc-MDP in 10 volunteers, after it was tested in laboratory animals. 99mTc-ABP has shorter mean residence time (MRT) and t 1/2 beta; is less protein bound; has a higher renal clearance; smaller Vdss, and similar bone uptake at 1 and 2 h. 99mTc-ABP gives less radiation exposure to the patient with a 740 MBq dose, and the quality of the bone scan is excellent. 99mTc-ABP is a better radiopharmaceutical than 99mTc-MDP for bone scanning.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Alendronate / analogs & derivatives*
  • Alendronate / blood
  • Alendronate / pharmacokinetics
  • Animals
  • Area Under Curve
  • Bone and Bones / diagnostic imaging*
  • Female
  • Half-Life
  • Humans
  • Male
  • Mice
  • Organotechnetium Compounds / blood
  • Organotechnetium Compounds / pharmacokinetics*
  • Rabbits
  • Radionuclide Imaging
  • Radiopharmaceuticals / blood
  • Radiopharmaceuticals / pharmacokinetics*
  • Rats
  • Rats, Wistar
  • Technetium Tc 99m Medronate / blood
  • Technetium Tc 99m Medronate / pharmacokinetics*
  • Tissue Distribution


  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • technetium Tc 99m alendronate
  • Alendronate
  • Technetium Tc 99m Medronate